Sophie Lotersztajn

List of Publications by Year
in descending order

49 papers	5,368 citations	136740 32 h-index	214527 47 g-index
49 all docs	49 docs citations	49 times ranked	7120 citing authors

#	Article	IF	Citations
1	CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine, 2006, 12, 671-676.	15.2	476
2	M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology, 2014, 59, 130-142.	3.6	450
3	Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology, 2005, 128, 742-755.	0.6	420
4	HEPATIC FIBROSIS: Molecular Mechanisms and Drug Targets. Annual Review of Pharmacology and Toxicology, 2005, 45, 605-628.	4.2	288
5	Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology, 2005, 42, 63-71.	3.6	269
6	Autophagy in liver diseases: Time for translation?. Journal of Hepatology, 2019, 70, 985-998.	1.8	252
7	Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology, 2011, 54, 1217-1226.	3.6	214
8	Macrophage autophagy protects against liver fibrosis in mice. Autophagy, 2015, 11, 1280-1292.	4.3	210
9	Mucosal-associated invariant T cells and disease. Nature Reviews Immunology, 2019, 19, 643-657.	10.6	197
10	Cellular Mechanisms of Tissue Fibrosis. 5. Novel insights into liver fibrosis. American Journal of Physiology - Cell Physiology, 2013, 305, C789-C799.	2.1	191
11	Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis. PLoS ONE, 2009, 4, e5844.	1.1	189
12	Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C. Gastroenterology, 2008, 134, 432-439.	0.6	174
13	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications, 2018, 9, 2146.	5.8	152
14	Pathophysiology of NASH: Perspectives for a Targeted Treatment. Current Pharmaceutical Design, 2013, 19, 5250-5269.	0.9	140
15	Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity. Diabetes, 2009, 58, 125-133.	0.3	127
16	Cannabinoid signaling and liver therapeutics. Journal of Hepatology, 2013, 59, 891-896.	1.8	119
17	The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusionâ€induced cardiomyopathy. FASEB Journal, 2009, 23, 2120-2130.	0.2	116
18	A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. Journal of Hepatology, 2020, 72, 528-538.	1.8	113

#	Article	IF	Citations
19	Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model. Environmental Health Perspectives, 2017, 125, 428-436.	2.8	98
20	Platelet-derived Growth Factor-BB and Thrombin Generate Positive and Negative Signals for Human Hepatic Stellate Cell Proliferation. Journal of Biological Chemistry, 1998, 273, 27300-27305.	1.6	94
21	Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology, 2010, 52, 1046-1059.	3.6	93
22	Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology, 2014, 59, 296-306.	3.6	93
23	Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB ₁) receptors in the regenerating liver. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6323-6328.	3.3	90
24	The sphingosine 1â€phosphate receptor S1P 2 triggers hepatic wound healing. FASEB Journal, 2007, 21, 2005-2013.	0.2	77
25	Autophagy: A Multifaceted Partner in Liver Fibrosis. BioMed Research International, 2014, 2014, 1-7.	0.9	77
26	The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. Scientific Reports, 2016, 6, 28806.	1.6	75
27	Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology, 2003, 125, 460-469.	0.6	72
28	Autophagy in chronic liver diseases: the two faces of Janus. American Journal of Physiology - Cell Physiology, 2017, 312, C263-C273.	2.1	62
29	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut, 2019, 68, 522-532.	6.1	59
30	Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opinion on Therapeutic Targets, 2007, 11, 403-409.	1.5	56
31	M2 Kupffer Cells Promote Hepatocyte Senescence. American Journal of Pathology, 2014, 184, 1763-1772.	1.9	51
32	LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling. Science Translational Medicine, 2020, 12, .	5.8	48
33	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	2.2	39
34	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. Journal of Lipid Research, 2019, 60, 1284-1292.	2.0	27
35	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	1.8	26
36	Targeting cell-intrinsic metabolism for antifibrotic therapy. Journal of Hepatology, 2021, 74, 1442-1454.	1.8	24

#	Article	IF	Citations
37	Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts. Journal of Hepatology, 2004, 41, 407-413.	1.8	23
38	Interleukinsâ€17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. Hepatology Communications, 2018, 2, 329-343.	2.0	19
39	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Hepatology, 2020, 71, 1750-1765.	3.6	18
40	LC3-associated phagocytosis in myeloid cells, a fireman that restrains inflammation and liver fibrosis, via immunoreceptor inhibitory signaling. Autophagy, 2020, 16, 1526-1528.	4.3	13
41	The liver X receptor in hepatic stellate cells: A novel antifibrogenic target?. Journal of Hepatology, 2011, 55, 1452-1454.	1.8	10
42	Statins Modulate Cyclooxygenaseâ€2 and Microsomal Prostaglandin E Synthaseâ€1 in Human Hepatic Myofibroblasts. Journal of Cellular Biochemistry, 2016, 117, 1176-1186.	1.2	9
43	Glutamate Signaling in Alcoholâ€associated Fatty Liver: â€œPas de Deuxâ€. Hepatology, 2020, 72, 350-352.	3.6	6
44	Targeting cannabinoid receptors in hepatocellular carcinoma?. Gut, 2016, 65, 1582-1583.	6.1	5
45	In vitro distinction between proinflammatory and antiinflammatory macrophages with gadoliniumâ€liposomes and ultrasmall superparamagnetic iron oxide particles at 3.0T. Journal of Magnetic Resonance Imaging, 2019, 49, 1166-1173.	1.9	4
46	Inflammation in alcohol-associated liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 58-66.	0.2	2
47	When Autophagy Chaperones Liver Metabolism. Cell Metabolism, 2014, 20, 392-393.	7.2	1
48	Endocannabinoids in the pathophysiology of obesity â€“ The liver. Drug Discovery Today Disease Mechanisms, 2010, 7, e185-e190.	0.8	0
49	Reply. Hepatology, 2014, 59, 353-354.	3.6	0